Home of Heart Recovery
Impella heart pumps have been shown to contribute to improvement in high-risk PCI, survival in cardiogenic shock, and cost-effective therapy design.
Learn more about the available clinical evidence on Impella Heart Pumps in the field of Protected PCI and cardiogenic shock on this page. Discover multimedia articles on the indication fields and our peer-to-peer community CAMP.
-
13
Include Impella heart pumps (nationally and internationally)
-
2x
Higher survival rate during ECMO therapy with Impella unloading (ECpella)3
-
76%
Reduction of heart failure symptoms NYHA Class III/IV symptom improvement in HRPCI patients1,2
Routine Impella CP Use Reduces 180-Day All-Cause Mortality in AMICS Due to STEMI
The DanGer Shock RCT4 confirms Impella CP® improves survival by 12.7%, compared to the control arm treated without Impella devices, in heart attack with shock.4 This independent investigator-initiated study represents a landmark as:
- The first RCT in AMICS trial history to achieve its primary endpoint.
- The first RCT in the MCS device trial history to demonstrate a survival benefit in AMICS.
EF Improvement Following Contemporary High-Risk PCI
RESTORE EF shows EF improved by 29% from overall baseline of 35% to 45% in high-risk PCI patients supported with Impella® heart pumps.
Clinical Evidence about Impella Heart Pumps
Improved Patient Management Through Continuous Product Innovation
Abiomed is constantly developing its product portfolio to achieve the best possible outcome for patients and users - in line with our mission: Patients first!
These product innovations and enhancements include not only changes to our heart pumps, but also software enhancements to the Automated Impella Controller (AIC) in the form of more accurate alarms, expanded metrics, and easier set-up.
-
10
Product innovations to improve user-friendliness and patient management
-
400+
Hospitals already benefit from Impella Connect®
-
9%
Reducation of bleeding through continuous improvements to the technology
Education Library - Education on Demand
Access Our Learning Resouces About Impella® Devices Wherever and Whenever You Want.
Contact Us
Do you want to learn more about Impella heart pumps or contact your dedicated Abiomed sales representative? Get in touch with us.
References
- O’Neill, et al. (2012). Circulation, 126 (14), 1717-1727.
- Wollmuth, J., Patel, M. et al. (2022). JSCAI, 100350. https://doi.org/10.1016/j.jscai.2022.100350.
- Pappalardo, et al. (2017). Eur J Heart Fail, 19 (3), 404-412.
- Møller, J., et al. (2024). Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock. N Engl J Med.
*based on onset of shock enrollment was permitted up to 12 h after PCI
NPS-4434